# Werkzaamheid en veiligheid van finerenon bij primair aldosteronisme

*geplaatst 2026-01-22 · Hypertensie · Hypertension · doi https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26048 · https://hartvaat.nl/2026/01/22/werkzaamheid-en-veiligheid-van-finerenon-bij-primair-aldosteronisme/*

Finerenon is een nieuwe niet-steroïdale mineralocorticoïdreceptorantagonist. Robuust bewijs over werkzaamheid en veiligheid bij primair aldosteronisme ontbrak. Deze prospectieve multicenter-studie onderzocht finerenon bij deze patiëntengroep.

## English: Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism: A Multicenter Prospective Study

This multicenter study provided the first prospective evidence on finerenone efficacy and safety in primary aldosteronism, testing the nonsteroidal MRA in the condition where aldosterone excess is the primary pathology.

## Abstract (original, from the publication)

Hypertension, Volume 83, Issue 5, Page e26048, May 1, 2026. BACKGROUND:Finerenone is a novel nonsteroidal mineralocorticoid receptor antagonist. However, robust evidence about its efficacy and safety in primary aldosteronism is scarce.METHODS:In this prospective, multicenter, single-arm, and exploratory trial, we enrolled adults (aged ≤75 years) with primary aldosteronism, an office blood pressure (BP) ranging from 140 to 180/90 to 120 mm Hg, and an estimated glomerular filtration rate ≥60 mL/min per 1.73 m². Eligible patients received finerenone (20–40 mg/d) treatment for 12 weeks. The primary outcome was the change in daytime systolic BP at 12 weeks.RESULTS:Fifty-seven patients were ultimately treated. Per-protocol analysis revealed that finerenone treatment significantly reduced mean daytime systolic BP (−6.69±1.60 mm Hg;P<0.001) and diastolic BP (−4.55±1.06 mm Hg;P<0.001) according to ambulatory monitoring. Mean office BP decreased even more substantially (systolic BP

Auteurs: Ping Li

---
Bron: Hypertension, https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26048. Bijgewerkt 2026-07-03T13:24:55Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.